PIIND2023-04-012023-06-30 PIIND2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member PIIND2023-04-012023-06-30in-bse-fin:OneOperatingExpenses02Member PIIND2023-04-012023-06-30in-bse-fin:OneOperatingExpenses03Member PIIND2023-04-012023-06-30in-bse-fin:OneOperatingExpenses04Member PIIND2023-04-012023-06-30in-bse-fin:OneOperatingExpenses05Member PIIND2023-04-012023-06-30in-bse-fin:OneOperatingExpenses06Member PIIND2023-04-012023-06-30in-bse-fin:OneOperatingExpenses07Member PIIND2023-04-012023-06-30in-bse-fin:OneOperatingExpenses08Member PIIND2023-04-012023-06-30in-bse-fin:OneOperatingExpenses09Member PIIND2023-04-012023-06-30in-bse-fin:OneOperatingExpenses10Member PIIND2023-06-30 PIIND2023-04-012023-06-30in-bse-fin:OneReportableSegmentRevenue01Member PIIND2023-04-012023-06-30in-bse-fin:OneReportableSegmentRevenue02Member PIIND2023-04-012023-06-30in-bse-fin:OneReportableSegmentRevenue03Member PIIND2023-04-012023-06-30in-bse-fin:OneReportableSegmentRevenue04Member PIIND2023-04-012023-06-30in-bse-fin:OneReportableSegmentResults01Member PIIND2023-04-012023-06-30in-bse-fin:OneReportableSegmentResults02Member PIIND2023-04-012023-06-30in-bse-fin:OneReportableSegmentResults03Member PIIND2023-04-012023-06-30in-bse-fin:OneReportableSegmentResults04Member PIIND2023-04-012023-06-30in-bse-fin:OneReportableSegmentAssets01Member PIIND2023-04-012023-06-30in-bse-fin:OneReportableSegmentAssets02Member PIIND2023-04-012023-06-30in-bse-fin:OneReportableSegmentAssets03Member PIIND2023-04-012023-06-30in-bse-fin:OneReportableSegmentAssets04Member PIIND2023-04-012023-06-30in-bse-fin:OneReportableSegmentLiabilities01Member PIIND2023-06-30in-bse-fin:OneReportableSegmentLiabilities01Member PIIND2023-04-012023-06-30in-bse-fin:OneReportableSegmentLiabilities02Member PIIND2023-06-30in-bse-fin:OneReportableSegmentLiabilities02Member PIIND2023-04-012023-06-30in-bse-fin:OneReportableSegmentLiabilities03Member PIIND2023-06-30in-bse-fin:OneReportableSegmentLiabilities03Member PIIND2023-04-012023-06-30in-bse-fin:OneReportableSegmentLiabilities04Member PIIND2023-06-30in-bse-fin:OneReportableSegmentLiabilities04Member PIIND2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member PIIND2023-04-012023-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member PIIND2023-04-012023-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 523642 PIIND NOTLISTED PI Industries Limited Equity 2023-04-01 2024-03-31 2023-08-09 2023-07-31 INR Millions First quarter 14:30:00 19:50:00 2023-08-09 2023-08-09 Not applicable Multi segment 2023-04-01 2023-06-30 Unaudited Consolidated 19104000000.00 469000000.00 19573000000.00 9719000000.00 677000000.00 -178000000.00 1735000000.00 43000000.00 697000000.00 2473000000.00 15166000000.00 4407000000.00 0.00 4407000000.00 807000000.00 -182000000.00 625000000.00 0.00 3782000000.00 0.00 0.00 0.00 47000000.00 3829000000.00 280000000.00 4109000000.00 3829000000.00 0.00 4109000000.00 0.00 152000000.00 1 25.24 25.24 0.00 0.00 25.24 25.24 1. The above Consolidated financial results were reviewed and recommended by the Audit Committee of the Board and approved by the Board of Directors at their meeting held on August 09, 2023. 2. Consolidated Financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time. 3. The Consolidated financial results include the results of the following entities namely, Parent Company a) Pl Industries Limited; Subsidiaries (including step down subsidiaries): b) PILL Finance and Investments Limited c) Pl Life Science and Research Limited d) Pl Japan Co. Limited e) Jivagro Limited f) Pl BIOFERMA Private Limited g) Pl FERMACHEM Private Limited h) Pl Health Sciences Limited i) Therachem Research Medilab (India) Private Limited j) Solis Pharmachem Private Limited k) Pl Health Sciences USA, LLC I) Pl Health Sciences Netherlands BV m) Archimica S.p.A Italy; Controlled trust: n) Pl ESOP Trust; o) Pl Kumiai Private Limited (Joint Venture) p) Solinnos Agro Sciences Private Limited (Associate). 4. The Figures for the quarter ended March 31, 2023 are the balancing figures between audited figures in respect of full financial year ended March 31, 2023 and the published unaudited year to date figures for the nine months period ended December 31, 2022. 5. The Company raised Rs. 20,000 million during the quarter ended 30th September 2020 through Qualified Institutional Placement (QIP) of equity shares. Out of the funds received of Rs. 19,750 million (net of expense of Rs. 250 million), the Company invested Rs. 8,430 million (including Rs. 865 million invested till March 31, 2023) in one of its subsidiary, Pl Health Sciences Limited. Balance funds of Rs. 11,320 million received pursuant to QIP remain invested in fixed deposits, liquid and other debt mutual funds. 6. During the quarter, Pl Health Sciences Limited has entered into a share purchase agreement dated 27th April 2023 for the acquisition of 100% shareholding of Therachem Research Medilab (India) Private Limited and Solis Pharmachem Private Limited . Further, Pl Health Sciences USA, LLC has entered into an asset purchase agreement dated 27th April 2023 for the acquisition of business of Therachem Research Medilab LLC, USA. These agreements were subject to satisfactory completion of conditions precedents as set out in the respective agreement, which were completed on June 02, 2023 end of business hours. Pl Health Sciences Netherlands BV has entered into a share purchase agreement dated 26th April 2023 for the acquisition of 100% shareholding of Archimica S.p.A, Italy and acquired 100% shares on 27th April 2023. These transactions have been accounted for in accordance with the acquisition method specified in Ind AS 103 Business Combination and the purchase consideration in excess of the provisional fair value of the net assets acquired amounting to Rs. 2,485 millon has been recognised as provisional goodwill. 7. The Board of Directors of Pl Health Sciences Limited, Therachem Research Medilab (India) Private Limited and Solis Pharmachem Private Limited, have approved scheme of arrangements for merger of Therachem Research Medilab (India) Private Limited and Solis Pharmachem Private Limited Into Pl Health Sciences Limited from the appointed date of June 02, 2023 (close of business hours). Accordingly, applications have been filed for approval with the Regional Director, Ministry of Corporate Affairs on July 11, 2023. 8. Segment information as per Ind AS 108 Operating Segments is as per annexure I. Advertisement & Sales Promotion 187000000.00 Environment & Pollution Control Expenses 274000000.00 Freight & Cartage 184000000.00 Legal & professional fees 268000000.00 Others 626000000.00 Power, Fuel & Water 520000000.00 Provision for Bad and Doubtful debts & Advances 63000000.00 Repairs & Maintenance - Others 56000000.00 Repairs & Maintenance - Plant and machinery 112000000.00 Travelling and Conveyance 183000000.00 Agro Chemicals 18661000000.00 Other Income 0.00 Pharma 443000000.00 Share of profit/(loss) from associate/ Joint venture 0.00 19104000000.00 0.00 19104000000.00 Agro Chemicals 4133000000.00 Other Income 469000000.00 Pharma -152000000.00 Share of profit/(loss) from associate/ Joint venture 47000000.00 4497000000.00 43000000.00 0.00 4454000000.00 Agro Chemicals 83928000000.00 Other Income 0.00 Pharma 13761000000.00 Share of profit/(loss) from associate/ Joint venture 0.00 97689000000.00 0.00 97689000000.00 Agro Chemicals 16093000000.00 Other Income 0.00 Pharma 5502000000.00 Share of profit/(loss) from associate/ Joint venture 0.00 21595000000.00 0.00 21595000000.00 Remeasurement gain /(loss) on defined benefits plans 7000000.00 7000000.00 2000000.00 Effective portion of gain / (loss) on cash flow hedges 457000000.00 Exchange difference on translation of foreign operations -22000000.00 435000000.00 160000000.00